Tag Archives: HHS
By Guest Blogger | Published: March 19, 2013
by Tom Norton As the US pharmaceutical industry anxiously watches the rapid onset of Obamacare, certainly one of the more pressing issues is the debate over the number of drugs that will be reimbursed in each therapeutic class under the Essential Health Benefits (EHB) program. To say that this is a critical concern for the […]
By Ben Comer | Published: February 5, 2013
Good science can’t be rushed, even when the lives of patients hang in the balance. But regulatory science, and its relationship to a drug’s commercial success or failure, can inadvertently block access to individual patients in their hour of need.
By Guest Blogger | Published: February 1, 2013
by Tom Norton This past week or so, with Obamacare’s start up less than a year away, we have been treated to several entertaining vignettes as the nation’s governors begin to wrestle with the realities of the new healthcare law.
By Guest Blogger | Published: December 19, 2012
by Tom Norton With the general election behind us, the anticipated avalanche of ObamaCare regulations has begun. Last week, it was reported that more than 13,000 pages of rules and regulations have been issued by HHS since Nov. 6th. A huge amount of activity, to be sure, but as stated, not surprising. That’s because the […]
By Jill Wechsler | Published: November 28, 2012
Recent change likely to boost drug coverage by plans, but with variation in formularies. Health plans offering coverage to individuals and small companies are more likely to cover multiple drugs in each class or category under revised regulations proposed by the Department of Health and Human Services in November. A key change in rules to […]